Eos SENOLYTIX to Present at Mitochondria Conference

HOUSTON, Sept. 22, 2026 /CourierPR/ -- Eos SENOLYTIX, Inc., a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging, announced its participation at the 17th World Congress on Targeting Mitochondria 2026, which will be held in Berlin from October 21 to 23, 2026. The company's lead candidate, MitoXcel™ geropeptide PTC-2105, is set to advance toward first-in-human studies for conditions such as sarcopenia and sarcopenic obesity.

Following the two addresses, Slawin and Szeto will co-host a panel discussion exploring the evolution of mitochondrial science from discovery to therapeutic application. Eos's approach is based on the hypothesis that addressing fundamental drivers of cellular dysfunction associated with aging may improve physiological function and mitigate the progression of a broad range of age-related conditions.

PTC-2105, Eos's lead product candidate, is a novel proprietary MitoXcel™ geropeptide designed to modulate mitochondrial function and selectively target senescent cells for self-elimination. The company is developing PTC-2105 initially for the treatment of sarcopenia, characterized by progressive loss of skeletal muscle mass, strength, and physical function, and sarcopenic obesity, a condition in sarcopenic patients that includes simultaneous excess adiposity.

Eos anticipates closing its merger with Pulmatrix, Inc. in the fourth quarter, subject to customary closing conditions. The proposed merger, which was previously announced in a Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on March 26, 2026, will see the business of Eos continue as the business of the combined company under the new ticker symbol MTXL.

The proposed merger is expected to close shortly thereafter, subject to customary closing conditions. Pulmatrix, Inc. (Nasdaq: PULM), a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs, entered into an agreement with Eos SENOLYTIX, Inc. (Eos) on March 26, 2026, for a plan of merger.

Eos's next generation mitochondria-targeted MitoXcel™ geropeptides, licensed from SENOTHERAPEUTIX, Inc., seek to build on the science behind Stealth Bio's FORZINITY™ (elamipretide), a tetrapeptide (4 amino acids) recently granted accelerated approval by the FDA for the treatment of Barth syndrome, a rare, serious, and life-threatening disease characterized by muscle weakness, chronic fatigue, and low muscle mass. FORZINITY was granted accelerated approval based on improvement in knee extensor muscle strength.

While Mighty Therapeutics, formerly known as Stealth Bio, is still required to conduct post-approval trials to confirm FORZINITY's long-term clinical effectiveness, FORZINITY remains the first FDA-approved therapy that directly targets mitochondria. The joint Mighty Therapeutics and University of Washington team was named a finalist and, in August 2026, a Milestone 2 Awardee in the $101 million XPRIZE Healthspan competition, based on pilot data evaluating elamipretide in older adults.

The proposed merger with Pulmatrix, Inc. is anticipated to close shortly thereafter, subject to customary closing conditions. Pulmatrix, Inc. (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, entered into an agreement with Eos SENOLYTIX, Inc. on March 26, 2026, for a plan of merger.

The proposed merger is expected to close shortly thereafter, subject to customary closing conditions. Pulmatrix, Inc. (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, entered into an agreement with Eos SENOLYTIX, Inc. on March 26, 2026, for a plan of merger.